A spiro bridged ring compound capable of modulating the activity of a farnesoid X receptor (FXR), a pharmaceutical composition thereof, and the use of the compound and the composition to treat an FXR-mediated disease in mammals, the compound having a structure shown in (I), or a pharmaceutically acceptable salt, hydrate, solvate, stereoisomer, tautomer, nitrogen oxide, metabolite, prodrug or mixture thereof.